Anti-hRANKL-hIgG2
-
Cat.code:
hrankl-mab2
- Documents
ABOUT
Anti-human RANKL (TNFSF11) - Denosumab biosimilar - CAS #615258-40-7
Anti-hRANKL-hIgG2 is a biosimilar antibody of Denosumab, a therapeutic antibody that targets the human RANKL (receptor activator of nuclear factor-κB ligand, or TNFSF11). This monoclonal antibody (mAb) blocks the interaction of RANKL with its receptor. The FDA has approved Denosumab for the treatment of osteoporosis and bone metastasis.
Anti-hRANKL-hIgG2 comprises the variable region of Denosumab and the IgG2 constant region of Denosumab with high effector functions.
This antibody can be used with HEK-Blue™ RANKL cells for screening and neutralization assays to block recombinant human RANKL -induced signaling (see figure).
Key features
- Each lot is functionally tested and validated.
- The complete sequence of the antibody construct was verified.
- The absence of endotoxins is determined using the EndotoxDetect™ assay.
All products are for research use only, and not for human or veterinary use.
SPECIFICATIONS
Specifications
Receptor activator of nuclear factor-κB ligand (RANKL, TNFSF11, CD254)
Human
ELISA, Neutralization assay
Sodium phosphate buffer with glycine, saccharose, and stabilizing agents
Negative (tested using EndotoxDetect™ assay)
ELISA, Neutralization assay
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:Anti-hRANKL-hIgG2
-
Cat code:hrankl-mab2
-
Quantity:100 µg
Shipping & Storage
- Shipping method: Room temperature
- -20°C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
Denosumab background
Denosumab is a therapeutic, fully human IgG2 mAb that blocks the interaction of human (h)RANKL with its receptor RANK and thus the downstream signaling. It targets the transmembrane and soluble forms of the human RANKL (receptor activator of nuclear factor-κB ligand, also known as member 11 of the tumor necrosis factor ligand superfamily (TNFSF11)) [1]. RANKL binding to its receptor RANK induces signaling in osteoclasts and is responsible for bone resorption. RANKL-RANK also plays a pivotal role in dendritic cell maturation and T-cell differentiation [2].
Human IgG2 is the second most common antibody present in serum. It is resistant to cleavage by proteolytic enzymes, due to a short hinge region. This isotype displays low complement-dependent cytotoxicity (CDC), very low antibody-dependent cellular phagocytosis (ADCP), and very low antibody-dependent cellular cytotoxicity (ADCC).
Denosumab has been approved by the FDA for the treatment of osteoporosis and bone metastasis [3].
References:
1. Ahern E. et al., 2018. Roles of the RANKL-RANK axis in antitumour immunity -implications for therapy. Nat Rev Clin Oncol. 15(11):676-693.
2. Cheng ML. & Fong L., 2014. Effects of RANKL-Targeted Therapy in Immunity and Cancer. Front Oncol. 3:329.
3. Zaheer S, et al., 2015. Denosumab for the treatment of osteoporosis. Expert Opin Drug Metab Toxicol. 2015 Mar;11(3):461-70. doi: 10.1517/17425255.2015.1000860
DOCUMENTS
Documents
Technical Data Sheet
Safety Data Sheet
Validation Data Sheet
Certificate of analysis
Need a CoA ?